Evolution of the Average Target: Corcept Therapeutics Incorporated

Evolution of the Average Target - Corcept Therapeutics Incorporated

Evolution of the Target Price: Corcept Therapeutics Incorporated

Evolution of the Target Price - Corcept Therapeutics Incorporated

Changes in Analyst Recommendations: Corcept Therapeutics Incorporated

1411c9f2fcdaa96bb4caedcb888.minD8E0TL_TijQQT4z3jQQR58efquWZvpUL_FsiDjFs.rnmCxClmX8SR1D0kqn-pNUIfo5LZzg9XiDOucpG2uAPRRLCDIH5fmZDacw~9f3f636b0b9e4c2d79e19912f024414f
08-18 Truist Adjusts Price Target on Corcept Therapeutics to $164 From $50, Maintains Buy Rating MT
05-13 Corcept Therapeutics Shares Rise After UBS Upgrade MT
05-13 UBS Upgrades Corcept Therapeutics to Buy From Neutral, Adjusts Price Target to $72 From $44 MT
05-04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
12-31 Truist Securities Lowers Corcept Therapeutics' Price Target to $50 From $135, Buy Rating Kept MT
12-31 Wolfe Research Downgrades Corcept Therapeutics to Underperform from Peer Perform, Price Target is $30 MT
12-16 UBS Initiates Corcept Therapeutics at Neutral With $95 Price Target MT
25-10-19 Corcept Therapeutics Incorporated Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment CI
25-07-31 Corcept Therapeutics Q2 revenue misses estimates RE
25-05-06 Truist Cuts Price Target on Corcept Therapeutics to $135 From $150, Keeps Buy Rating MT
25-03-31 Piper Sandler Raises Corcept Therapeutics' Price Target to $128 From $78, Maintains Overweight Rating MT
25-03-31 Truist Securities Adjusts Corcept Therapeutics Price Target to $150 From $76, Maintains Buy Rating MT
25-03-31 HC Wainwright Adjusts Price Target on Corcept Therapeutics to $150 From $115, Maintains Buy Rating MT
24-09-30 Truist Raises Price Target on Corcept Therapeutics to $76 From $65, Keeps Buy Rating MT
24-06-04 Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating MT
24-05-02 Truist Lifts Corcept Therapeutics' PT to $44 From $42 After Raised Kolym Guidance, Keeps Buy Rating MT
24-02-16 Truist Securities Adjusts Price Target on Corcept Therapeutics to $42 From $36, Maintains Buy Rating MT
24-01-02 HC Wainwright Adjusts Corcept Therapeutics' Price Target to $28 From $34, Keeps Buy Rating MT
23-12-13 Canaccord Genuity Adjusts Corcept Therapeutics' Price Target to $38 From $37, Keeps Buy Rating MT
23-11-06 Truist Upgrades Corcept Therapeutics to Buy Rating From Hold, Adjusts Price Target to $38 From $29 MT
23-11-02 HC Wainwright Adjusts Price Target on Corcept Therapeutics to $34 From $32, Keeps Buy Rating MT
23-08-25 Canaccord Genuity Adjusts Price Target on Corcept Therapeutics to $35 From $34, Maintains Buy Rating MT
23-08-03 Truist Securities Adjusts Price Target on Corcept Therapeutics to $29 From $26, Maintains Hold Rating MT
23-08-03 HC Wainwright Adjusts Price Target on Corcept Therapeutics to $32 From $30, Maintains Buy Rating MT
23-05-26 Truist Securities Adjusts Price Target on Corcept Therapeutics to $26 From $28, Maintains Hold Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+60.98%
+4.04%
+3.97%
-1.12%
-3%
+12.65%
-3.77%
+23.18%
-11.3%
+0.7%
Average +8.63%
Weighted average by Cap. +3.20%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
87.59USD
Average target price
141.00USD
Spread / Average Target
+60.98%
High Price Target
165.00USD
Spread / Highest target
+88.38%
Low Price Target
50.00USD
Spread / Lowest Target
-42.92%

Analyst Consensus Detail

Analyst consensus - Corcept Therapeutics Incorporated

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Corcept Therapeutics Incorporated
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Corcept Therapeutics Incorporated
  1. Stock Market
  2. Stocks
  3. CORT Stock
  4. Consensus Corcept Therapeutics Incorporated